Alphamab Oncology disclosed a further on-market share repurchase on 14 October 2026, acquiring 140,000 ordinary shares at prices between HKD 6.895 and HKD 7.000, for a total consideration of HKD 0.97 million.
The transaction reduced the company’s issued share capital (excluding treasury shares) by 0.0145%, from 966.58 million to 966.44 million shares, while lifting the treasury-share balance from 7.81 million to 7.95 million. Total issued shares, including treasury stock, remain unchanged at 974.38 million.
Key data: • Volume-weighted average repurchase price: HKD 6.9634 • Cumulative repurchases under the current mandate (granted 12 June 2026): 2.07 million shares, equating to 0.21% of issued shares as at the mandate date • Authorised headroom under the mandate: up to 96.85 million shares remain available for buyback • Post-repurchase moratorium: no new share issuance or treasury-share sales may occur before 13 November 2026, in line with Hong Kong Listing Rules
All repurchases were executed on the Hong Kong Stock Exchange and the repurchased shares will be retained as treasury stock. The company confirmed compliance with all Main Board listing requirements and reported no material changes to the previously issued explanatory statement.
Comments